» Articles » PMID: 37361215

Circular RNAs in Gynecologic Cancers: Mechanisms and Implications for Chemotherapy Resistance

Overview
Journal Front Pharmacol
Date 2023 Jun 26
PMID 37361215
Authors
Affiliations
Soon will be listed here.
Abstract

Chemotherapy resistance remains a major challenge in the treatment of gynecologic malignancies. Increasing evidence suggests that circular RNAs (circRNAs) play a significant role in conferring chemoresistance in these cancers. In this review, we summarize the current understanding of the mechanisms by which circRNAs regulate chemotherapy sensitivity and resistance in gynecologic malignancies. We also discuss the potential clinical implications of these findings and highlight areas for future research. CircRNAs are a novel class of RNA molecules that are characterized by their unique circular structure, which confers increased stability and resistance to degradation by exonucleases. Recent studies have shown that circRNAs can act as miRNA sponges, sequestering miRNAs and preventing them from binding to their target mRNAs. This can lead to upregulation of genes involved in drug resistance pathways, ultimately resulting in decreased sensitivity to chemotherapy. We discuss several specific examples of circRNAs that have been implicated in chemoresistance in gynecologic cancers, including cervical cancer, ovarian cancer, and endometrial cancer. We also highlight the potential clinical applications of circRNA-based biomarkers for predicting chemotherapy response and guiding treatment decisions. Overall, this review provides a comprehensive overview of the current state of knowledge regarding the role of circRNAs in chemotherapy resistance in gynecologic malignancies. By elucidating the underlying mechanisms by which circRNAs regulate drug sensitivity, this work has important implications for improving patient outcomes and developing more effective therapeutic strategies for these challenging cancers.

Citing Articles

The emerging role of circular RNAs in cisplatin resistance in ovarian cancer: From molecular mechanism to future potential.

Malek Mohammadi M, Rismanchi H, Esmailzadeh S, Farahani A, Hedayati N, Alimohammadi M Noncoding RNA Res. 2024; 9(4):1280-1291.

PMID: 39040815 PMC: 11261309. DOI: 10.1016/j.ncrna.2024.05.005.


circRNAs in Endometrial Cancer-A Promising Biomarker: State of the Art.

Wlodarczyk K, Kurylo W, Pawlowska-Lachut A, Skiba W, Suszczyk D, Pieniadz P Int J Mol Sci. 2024; 25(12).

PMID: 38928094 PMC: 11203539. DOI: 10.3390/ijms25126387.


Drug resistance in ovarian cancer: from mechanism to clinical trial.

Wang L, Wang X, Zhu X, Zhong L, Jiang Q, Wang Y Mol Cancer. 2024; 23(1):66.

PMID: 38539161 PMC: 10976737. DOI: 10.1186/s12943-024-01967-3.


The emerging roles of long non-coding RNA (lncRNA) H19 in gynecologic cancers.

Ghasemian M, Zehtabi M, Gale Dari M, Pour F, Azizi Tabesh G, Moramezi F BMC Cancer. 2024; 24(1):4.

PMID: 38166752 PMC: 10763168. DOI: 10.1186/s12885-023-11743-z.


The role of circRNAs in regulation of drug resistance in ovarian cancer.

Zhan J, Li Z, Lin C, Wang D, Yu L, Xiao X Front Genet. 2023; 14:1320185.

PMID: 38152652 PMC: 10751324. DOI: 10.3389/fgene.2023.1320185.

References
1.
Yi H, Han Y, Li Q, Wang X, Xiong L, Li S . Circular RNA circ_0004488 Increases Cervical Cancer Paclitaxel Resistance via the miR-136/MEX3C Signaling Pathway. J Oncol. 2022; 2022:5435333. PMC: 9691333. DOI: 10.1155/2022/5435333. View

2.
Alatise K, Gardner S, Alexander-Bryant A . Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets. Cancers (Basel). 2022; 14(24). PMC: 9777152. DOI: 10.3390/cancers14246246. View

3.
Karami Fath M, Azargoonjahromi A, Kiani A, Jalalifar F, Osati P, Akbari Oryani M . The role of epigenetic modifications in drug resistance and treatment of breast cancer. Cell Mol Biol Lett. 2022; 27(1):52. PMC: 9238060. DOI: 10.1186/s11658-022-00344-6. View

4.
Gao X, Tian X, Huang Y, Fang R, Wang G, Li D . Role of circular RNA in myocardial ischemia and ageing-related diseases. Cytokine Growth Factor Rev. 2022; 65:1-11. DOI: 10.1016/j.cytogfr.2022.04.005. View

5.
Pastwinska J, Karas K, Karwaciak I, Ratajewski M . Targeting EGFR in melanoma - The sea of possibilities to overcome drug resistance. Biochim Biophys Acta Rev Cancer. 2022; 1877(4):188754. DOI: 10.1016/j.bbcan.2022.188754. View